Immutep
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immutep and other ETFs, options, and stocks.About IMMP
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731).
CEOMarc Voigt
CEOMarc Voigt
Employees—
Employees—
HeadquartersSydney, New South Wales (NSW)
HeadquartersSydney, New South Wales (NSW)
Founded1987
Founded1987
Employees—
Employees—
IMMP Key Statistics
Market cap283.32M
Market cap283.32M
Price-Earnings ratio-8.90
Price-Earnings ratio-8.90
Dividend yield—
Dividend yield—
Average volume176.34K
Average volume176.34K
High today$1.98
High today$1.98
Low today$1.86
Low today$1.86
Open price$1.91
Open price$1.91
Volume86.23K
Volume86.23K
52 Week high$3.12
52 Week high$3.12
52 Week low$1.32
52 Week low$1.32
IMMP News
TipRanks 7d
Immutep’s Promising Phase 1 INSIGHT-003 Results Drive Buy RatingAnalyst Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report) and keeping the price target at $12.00. Confident Investing...
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%